0.4421
price down icon12.46%   -0.0629
after-market Dopo l'orario di chiusura: .44 -0.0021 -0.48%
loading
Precedente Chiudi:
$0.505
Aprire:
$0.5045
Volume 24 ore:
891.60K
Relative Volume:
0.88
Capitalizzazione di mercato:
$951.02K
Reddito:
-
Utile/perdita netta:
$-22.56M
Rapporto P/E:
-0.2291
EPS:
-1.93
Flusso di cassa netto:
$-16.12M
1 W Prestazione:
-34.99%
1M Prestazione:
-51.60%
6M Prestazione:
-77.90%
1 anno Prestazione:
-23.91%
Intervallo 1D:
Value
$0.4326
$0.5045
Intervallo di 1 settimana:
Value
$0.4326
$0.686
Portata 52W:
Value
$0.231
$4.3785

Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile

Name
Nome
Cyclacel Pharmaceuticals Inc
Name
Telefono
908-517-7330
Name
Indirizzo
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Name
Dipendente
12
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
CYCC's Discussions on Twitter

Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-07-18 Ripresa Oppenheimer Outperform
2020-04-27 Ripresa ROTH Capital Buy
2018-09-07 Iniziato Ladenburg Thalmann Buy
2015-10-16 Iniziato H.C. Wainwright Buy
2010-02-04 Iniziato Roth Capital Buy
2009-10-28 Iniziato Merriman Buy
2008-08-12 Iniziato Piper Jaffray Buy
2008-03-12 Reiterato Cantor Fitzgerald Buy
2008-03-12 Reiterato Collins Stewart Buy
2008-03-12 Reiterato Needham & Co Buy
2007-11-27 Reiterato Cantor Fitzgerald Buy
2007-08-10 Reiterato Cantor Fitzgerald Buy
2007-06-04 Reiterato Needham & Co Buy
2007-04-23 Iniziato Lazard Capital Buy
2007-04-10 Iniziato Cantor Fitzgerald Buy
Mostra tutto

Cyclacel Pharmaceuticals Inc Borsa (CYCC) Ultime notizie

pulisher
Nov 04, 2024

Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com

Nov 04, 2024
pulisher
Oct 28, 2024

Cyclacel stock plunges to 52-week low at $0.74 amid market challenges - Investing.com India

Oct 28, 2024
pulisher
Oct 24, 2024

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - The Manila Times

Oct 24, 2024
pulisher
Oct 23, 2024

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - ForexTV.com

Oct 23, 2024
pulisher
Oct 23, 2024

Nasopharyngeal Cancer Market Report: Growth Forecast and Key - openPR

Oct 23, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart

Oct 22, 2024
pulisher
Oct 21, 2024

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Stock Sentiment: What’s Wall Street Saying? - Stocks Register

Oct 21, 2024
pulisher
Oct 13, 2024

CYCCPCyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Latest Stock News & Market Updates - StockTitan

Oct 13, 2024
pulisher
Oct 12, 2024

Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN

Oct 12, 2024
pulisher
Oct 11, 2024

Cyclacel stock plunges to 52-week low, touches $0.8 By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 09, 2024

Cyclacel stock plunges to 52-week low, touches $0.8 - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

CYCCCyclacel Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan

Oct 09, 2024
pulisher
Oct 09, 2024

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - The Manila Times

Oct 09, 2024
pulisher
Oct 01, 2024

Cyclacel stock plunges to 52-week low at $0.95 amid market challenges - Investing.com Australia

Oct 01, 2024
pulisher
Oct 01, 2024

Cyclacel stock plunges to 52-week low at $0.95 amid market challenges By Investing.com - Investing.com South Africa

Oct 01, 2024
pulisher
Sep 25, 2024

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com

Sep 25, 2024
pulisher
Sep 16, 2024

Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga

Sep 16, 2024
pulisher
Sep 16, 2024

(CYCCP) Trading Report - Stock Traders Daily

Sep 16, 2024
pulisher
Sep 12, 2024

Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Sep 12, 2024
pulisher
Sep 06, 2024

Cyclacel halts dividend on preferred stock - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada

Sep 06, 2024
pulisher
Sep 04, 2024

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com

Sep 04, 2024
pulisher
Sep 03, 2024

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com

Sep 03, 2024
pulisher
Sep 03, 2024

Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga

Sep 03, 2024
pulisher
Sep 02, 2024

Cyclacel Pharmaceuticals Inc (CYCC)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Metric Analysis: Cyclacel Pharmaceuticals Inc (CYCC)’s Key Ratios in the Limelight - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

You might want to take a look at Cyclacel Pharmaceuticals Inc (CYCC) now - SETE News

Sep 02, 2024
pulisher
Aug 31, 2024

How To Trade (CYCCP) - Stock Traders Daily

Aug 31, 2024
pulisher
Aug 30, 2024

Cyclacel Pharmaceuticals faces potential Nasdaq delisting - Investing.com India

Aug 30, 2024
pulisher
Aug 30, 2024

Cyclacel Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com UK

Aug 30, 2024
pulisher
Aug 30, 2024

Geopark Ltd, Cyclacel Pharmaceuticals, Another 3 Companies Have A High Estimated Dividend Yield - Via News Agency

Aug 30, 2024
pulisher
Aug 28, 2024

Cyclacel stock plunges to 52-week low at $1.13 amid market challenges - Investing.com

Aug 28, 2024
pulisher
Aug 26, 2024

Cyclacel Pharmaceuticals faces Nasdaq delisting - Investing.com

Aug 26, 2024
pulisher
Aug 26, 2024

Cyclacel Pharmaceuticals faces Nasdaq delisting By Investing.com - Investing.com UK

Aug 26, 2024
pulisher
Aug 26, 2024

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call Transcript - MSN

Aug 26, 2024
pulisher
Aug 22, 2024

Cyclacel Pharmaceuticals changes its auditor - Investing.com

Aug 22, 2024
pulisher
Aug 22, 2024

Cyclacel Pharmaceuticals changes its auditor By Investing.com - Investing.com UK

Aug 22, 2024
pulisher
Aug 19, 2024

Cyclacel stock hits 52-week low at $1.21 amid market challenges - Investing.com

Aug 19, 2024
pulisher
Aug 18, 2024

Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Aug 18, 2024

Cyclacel Pharmaceuticals Inc Azioni (CYCC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Cyclacel Pharmaceuticals Inc Azioni (CYCC) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Rombotis Spiro George
President and CEO
Dec 21 '23
Buy
3.31
6,070
20,122
68,658
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):